Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 66.7%

Overall survival† · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.63 [0.6, 0.66]
764 participants
High

Overall survival† · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.42 [0.37, 0.48]
418 participants
High

Overall survival · people with cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found